CymaBay Therapeutics, Inc.

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Report date

12/31/2023

Quarter

2023 Q4

Filed

2/14/2024

Shares

85,842

Value ($000)

2,028

Weight

0.0%

2019 Q4 - 2023 Q4 (8 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2023 Q4	2/14/2024	2,028	0.0%	85,842	12/31/2023
2023 Q3	11/13/2023	1,135	0.0%	76,126	9/30/2023
2023 Q2	8/11/2023	602	0.0%	69,035	6/30/2023
2023 Q1	5/15/2023	602	0.0%	69,035	3/31/2023
2021 Q1	5/14/2021	498	0.0%	109,621	3/31/2021
2020 Q4	3/1/2021	490	0.0%	85,430	12/31/2020
2020 Q1	5/15/2020	162	0.0%	109,476	3/31/2020
2019 Q4	2/14/2020	127	0.0%	64,951	12/31/2019